As a result of global concern about rising drug costs, many US payers and European agencies have partnered with pharmaceutical companies in performance-based risk-sharing arrangements (PBRSAs), by which manufacturers share financial risk with health care purchasing entities and authorities. This study, coauthored by Andrew Parece in the Journal of Managed Care & Specialty Pharmacy, reports on US health care payer insights into several different PBRSA aspects (e.g., appropriate diseases, required outcomes data, critical contracting points, and methods of facilitation), which have not previously been collectively assessed. Using a web-based survey, 27 US payers provided feedback on 51 active PBRSAs at the time of the survey, as well as on their past and current negotiation experiences.
To read the study, click here.
Gene therapy competitive dynamics: Winner takes all?
This article was originally published in Cell & Gene. It has also been published in Cell & Gene‘s sister publication, OutSourced Pharama. With many gene...